## **Patient Assistance Program Application**



#### PATIENT CHECKLIST FOR SUBMITTING AN APPLICATION

Read the Patient Declaration and Patient Authorization to Share Health Information on page 4, then complete all relevant patient	Ask your Healthcare Professional (HCP) to complete, and sign and date page 3
information on page 2, and <b>sign and date</b> as required  ☐ Include a copy of the <b>front and back</b> of your insurance card  ☐ <b>Proof of income</b> (Choose one): Check the box in Section 4	☐ Submit completed pages <b>2 and 3 only</b> with documentation to <b>Mail:</b> Johnson & Johnson Patient Assistance Foundation, Inc. Patient Assistance Program
on page 2 <b>OR</b> Include a copy of your most recent 1040 or 1040 EZ Federal tax return	PO Box 0367, Chesterfield, MO 63006 <b>Fax:</b> 1-888-526-5168

#### Missing information and/or required documents may delay processing of application.

If you have questions about Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) or how to complete this form, please contact us at 1-800-652-6227, 9am – 6pm EST, Monday through Friday.

#### MEDICATIONS AVAILABLE THROUGH THE PATIENT ASSISTANCE PROGRAM

#### Medications shipped to the patient's residence

BALVERSA® (erdafitinib) Tablets ERLEADA® (apalutamide) Tablets

IMBRUVICA® (ibrutinib) Capsules or Tablets

**ZYTIGA®** (abiraterone acetate) Tablets

#### Medications shipped to the HCP's office

DARZALEX® (daratumumab) Injection for intravenous infusion

**DARZALEX** *FASPRO*® (daratumumab and hyaluronidase-fihj), Injection for subcutaneous use

HALDOL® Decanoate\* (haloperidol decanoate) Injection for extended-duration for effect

**INVEGA SUSTENNA®\*** (paliperidone palmitate) Extended-release Injectable Suspension

**INVEGA TRINZA**®\* (paliperidone palmitate) Extended-release Injectable Suspension

MONOVISC® (high molecular weight hyaluronan) Injection ORTHOVISC® (high molecular weight hyaluronan) Injection

REMICADE®\* (infliximab) Intravenous Infusion

RISPERDAL CONSTA®\* (risperidone) Long-acting Injection

RYBREVANT™ (amivantamab-vmjw) Injection, for intravenous use

SIMPONI ARIA®\* (golimumab) Intravenous Infusion

STELARA®† (ustekinumab) Injection, for subcutaneous or intravenous use

**TREMFYA®** (guselkumab) Prefilled syringe or One-Press patient-controlled injector

YONDELIS® (trabectedin) Injection for intravenous infusion

Medications available through retail or specialty pharmacy. HCP must provide a prescription.

CONCERTA®\* (methylphenidate HCI) Extended-release Tablets CII

EDURANT® (rilpivirine) Tablets

ELMIRON® (pentosan polysulfate sodium) Capsules

INTELENCE® (etravirine) Tablets

INVOKAMET®\* (canagliflozin/metformin HCI) Tablets

INVOKAMET® XR\* (canagliflozin/metformin HCI) Extended-release Tablets

INVOKANA® (canagliflozin) Tablets PONVORY™ (ponesimod) Tablets

PREZCOBIX® (darunavir 800mg/cobicistat 150mg) Tablets

PREZISTA® (darunavir) Tablets or Oral Suspension

PROCRIT®\* (epoetin alfa) Injection, for subcutaneous or intravenous use

SIMPONI®\* (golimumab) SmartJect® or Prefilled syringe

SIRTURO®\* (bedaquiline) Tablets

SPORANOX®\* (itraconazole) Capsules or Oral Solution

SPRAVATO®\* (esketamine) Nasal Spray CIII, for intranasal use

STELARA®† (ustekinumab) Injection, for subcutaneous or intravenous use

 $\textbf{SYMTUZA}^{\texttt{@*}} \textbf{ (} \textit{darunavir, cobicistat, emtricitabine, and }$ 

tenofovir alafenamide) Tablets

TREMFYA® (guselkumab) Prefilled syringe or One-Press

patient-controlled injector

XARELTO®\* (rivaroxaban) Tablets

\*Please read full Prescribing Information, including Boxed Warning.

†May be distributed via pharmacy or shipped to HCP.

The Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is an independent, non-profit organization that is committed to helping eligible patients without insurance coverage receive prescription products donated by Johnson & Johnson operating companies.

### You may be eligible for our free prescription program for up to one year if you meet the requirements below:

- You have been prescribed a Johnson & Johnson operating company donated medication
- You meet the eligibility income requirements for the medication(s)
- You don't have insurance **or** medicine is not covered
  - Some patients with Medicare Prescription Drug Coverage (Part D) who cannot afford their medicines and who meet certain financial criteria may also be eligible for assistance. A report from your pharmacy or an Explanation of Benefits (EOB) statement from your insurer that shows your out-of-pocket costs for the current year can be requested and may be submitted with your application. In order to qualify for the program, you must spend 4% or more of your gross annual income on prescription drugs.
- · You live in the United States or a U.S. territory
- · You are being treated by a U.S. licensed doctor as an outpatient

## **Patient Assistance Program Application**



**TO BE COMPLETED BY THE PATIENT** See checklist on page 1—all information is required.

1 Patie	nt Information				
Name:		Phone:		Email:	
	#:				
	t, City, State, ZIP):				
	icial Information				
	Select one of the options below <b>ONLY</b> if y	you do not chack the	Total Gross Ye	arly Income	
box in Section 4	4)			old: \$	
	y most recent 1040 or 1040EZ Federal ta	x return is attached.	Household Siz	e	
☐ I do not file	for SIRTURO®* applications.) Federal taxes			self, the number of people v	
	be reviewed and additional documentation requ	ested.)	your home and	are dependent on your ho	usehold income:
3 Healt	thcare Insurance Informatio	<b>n</b> (Select all that apply.)	Please attach	a copy of your insuran	ce card.
Subscriber Nar	me:	Date of Bi	rth:	Relationship to Pat	ient:
Primary Plan N	ame:	Secondary	y Plan Name:		
☐Check if no	insurance		ID/Policy#	Group#	Phone
Prescription	n Insurance/Medicare Part D Plan				
Plan Name:	Fax:				
Rx BIN #: _	Rx PCN:				
☐Private/Co	mmercial Insurance				
Medicaid					
Medicare P	art B				
☐ Medicare A	<u>-</u>				
☐ Veterans A					
□ ADAP AIDS					
Other:	Patient Assistance Program				
4 Patie	ent Declaration/Authorization	on to Assign Rep	resentative f	or Program Enroll	ment
My signature Information on to discuss my a and other issue	d date required before submission below indicates that I have read, under page 4. If I have listed an authorized repreparation with this person. This include as related to my application and participate on my behalf regarding my application	erstand, and agree to the resentative below, I pernous the status of my application, throughout my enr	nit the Johnson & Jo cation, insurance a	ohnson Patient Assistance nd financial questions, any	Foundation, Inc. (JJPAF) missing documentation,
CHECK THE BOX:	Applicant Financial Verifi I also understand that JJPA Administrators") may obtain my income or credit standing verification and acknowledge for purposes of determining r	F and the vendors asso a credit report or inves , to determine my eligib that such authorization	ociated with admin stigative credit repo ility for the Progran n extends to consu	ort about me which may c n. I hereby authorize such (	ontain information as to credit report and income
	Patient Name (print):			Date:	
PLEASE	Authorized Representative Name (prin				
COMPLETE, SIGN &	Relationship to Patient (print if applical	ole):		Phone:	
DATE:		,		<b>.</b>	
	Patient Signature/Authorized Represe			Date	

<sup>\*</sup>Please read full Prescribing Information, including Boxed Warning.

## **Patient Assistance Program Application**



## TO BE COMPLETED BY THE HEALTHCARE PROFESSIONAL (HCP)—all information is required.

		Date of Birth:
ICD Code (HCP-administered products on	ly):	
Name of Product:		
Strength:	Sig: _	
Quantity:	Days' Supply:	Number of Refills (maximum 11):
BALVERSA®, ERLEADA®, IMBRU	JVICA®, or ZYTIGA®:	HIV Medication:
If you are a prescriber in New York, Sour requesting BALVERSA®, ERLEADA®, IM attach prescription on your state official		<ul> <li>Check if patient is currently taking: ☐PREZISTA® ☐PREZCOBIX®</li> <li>☐INTELENCE® ☐EDURANT® ☐SYMTUZA®*</li> <li>PROCRIT®*:</li> </ul>
BALVERSA®, ERLEADA®, IMBRU	JVICA®, or ZYTIGA®:	Hemoglobin level based on most recent lab results:
List any patient allergies:		Required: Is the patient being treated on renal dialysis? □Yes <sup>†</sup> □No  RYBREVANT™:
BALVERSA®, ERLEADA®, IMBRU	or NKDA	<ul> <li>Has the patient tested positive for EGFR exon 20 insertion mutation?</li> <li>Yes \( \subseteq \text{No} \)</li> </ul>
List patient's current medications:	JVICA®, OF Z I TIGA®:	Select STELARA® Distribution Option (must select one):  ☐ Ship to HCP's office
		Retail or specialty pharmacy. HCP must provide a prescription.
	or $\square$ none	Select TREMFYA® Distribution Option (must select one):
<b>BALVERSA®:</b> Has the patient tested positive for Fe	0FP2	☐ Ship to HCP's office ☐ Retail or specialty pharmacy. HCP must provide a prescription.
rias the patient tested positive for the	diri: Lies Lino	Tetalion specialty pharmacy. For must provide a prescription.
2 HCP Information		
lame:	Site	Name:
Site Contact:	Busi	Name:ness Hours:
Site Contact:	Busi	ness Hours:
Site Contact: Address (City, State, ZIP): Phone:	Busi	ness Hours:Email:
Site Contact: Address (City, State, ZIP): Phone: Tax ID #:	Busi Fax: NPI # (required):	ness Hours:
Site Contact: Address (City, State, ZIP): Phone: Fax ID #: State License # (required):	Busi Fax: NPI # (required): Expiration (mm/yyyy):	ness Hours:Email:DEA # (required):
Site Contact: Address (City, State, ZIP): Phone:  Tax ID #: State License # (required): Collaborating MD (for mid-level providers	Busi Fax: NPI # (required): Expiration (mm/yyyy): s):	ness Hours:Email:  DEA # (required):  Collaborating MD NPI # (required):
Contact:	Fax: Fax: NPI # (required): Expiration (mm/yyyy):s): (PTAN) (required if the patient has Medical	DEA # (required): Collaborating MD NPI # (required):are):
Site Contact:  Address (City, State, ZIP):  Phone:  Tax ID #:  State License # (required):  Collaborating MD (for mid-level providers  Provider Transaction Access Number	Fax:  NPI # (required):  Expiration (mm/yyyy):  s):  (PTAN) (required if the patient has Medical response)  r SPRAVATO® REMS-Certified Treatment	Email:
Contact:	Fax:  NPI # (required):  Expiration (mm/yyyy):  s):  (PTAN) (required if the patient has Medical response):  SPRAVATO® REMS-Certified Treatment Contact	Email:  DEA # (required):  Collaborating MD NPI # (required):  are):  ent Center Address (if different from above):  ct Name for Shipment:
Site Contact:	Fax:  NPI # (required):  Expiration (mm/yyyy):  SS):  (PTAN) (required if the patient has Medical response of the patient has Medical resp	Email:
Address (City, State, ZIP):	Fax:  NPI # (required):  Expiration (mm/yyyy):  (PTAN) (required if the patient has Medical Section of the patient has Medical Section of the patient has Medical of the patient has Me	Email:
Address (City, State, ZIP):	Fax:  NPI # (required):  Expiration (mm/yyyy):  SS):  (PTAN) (required if the patient has Medical response of the patient has Medical resp	Email:
Address (City, State, ZIP):	Fax:  NPI # (required):  Expiration (mm/yyyy):  (PTAN) (required if the patient has Medical Section of the patient has Medical Section of the patient has Medical of the patient has Me	Email:

<sup>\*</sup>Please read full Prescribing Information, including Boxed Warning.

<sup>†</sup>Contact Amgen Inc. 1-800-772-6436.

#### DO NOT SUBMIT THIS PAGE—IT IS FOR PATIENT AND HEALTHCARE PROFESSIONAL RECORDS ONLY

## **Patient Assistance Program Application**



#### PATIENT DECLARATION AND PATIENT AUTHORIZATION TO SHARE HEALTH INFORMATION

Please read, sign and date on page 2, Patient Section 4.

#### I promise:

- The information on this form is correct and complete including all copies of documents proving my income.
- The product(s) provided under this patient assistance program will not be sold or traded.
- I will notify the Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) Patient Assistance Program ("Program") within thirty (30) days if there is any change in the status of my eligibility (related to changes in income or health coverage) to receive products through this program. This includes a change in my eligibility to participate in the Medicare program due to changes in my age or disability status or my enrollment in Medicare Part D.
- Not to attempt to claim or submit any costs associated with the medicine(s) I receive under the Johnson & Johnson Patient Assistance Foundation, Inc. Patient Assistance Program to any person or entity, including my Medicare Part D plan.
- Not to seek true out-of-pocket (TrOOP) credit under the Medicare Part D program for the cost of the medicine(s) I receive under this program.

## I authorize the following communications:

- Specifically, I authorize JJPAF to contact me to request my assistance with analysis related to the quality and efficacy of the JJPAF Program.
- When signing this application, I am agreeing to allow the manufacturer or its agent to contact me or my healthcare provider for additional information, if needed, to evaluate any adverse event or product complaint I or my provider reported on my behalf.
- The Program to contact my insurer, other potential funding sources, including the Centers for Medicare and Medicaid Services, social workers, or patient advocacy organizations on my behalf in order to determine if I am eligible for health insurance coverage or other funds, and disclose to them information contained in my JJPAF Program application or information about my prescribed medications and medical condition that has been provided by my physician, healthcare provider, or pharmacist.

# I understand that JJPAF and the vendors associated with administrating the Program (collectively the "Program Administrators"):

- Reserve the right without notice to change the application form, change the Program or Program criteria, or terminate my enrollment at any time, without notice.
- May request and obtain information about my or my family's income, including verification of my income through third-party sources.

## Patient Authorization To Share Health Information: By signing on page 2, I hereby authorize:

- My doctor(s), pharmacy and other healthcare providers, and my health plan or insurers ("Entities") to disclose to and share with JJPAF, the Program Administrators and their affiliates, agents, contractors, representatives, service providers, and assignees ("JJPAF Recipients"), my individually identifiable health information, which may include my full name, demographic information, financial information, and information related to medical condition, treatment, care management, health insurance and benefits, medication history, and prescriptions (collectively, "Health Information"), whether in written or verbal form, including portions of my medical record.
- The JJPAF Recipients to access, obtain, use, disclose, receive, and maintain my Health Information for purposes of processing this Application, verifying the information provided in this Application, assisting in the identification of or determining eligibility under the Program and other patient assistance resources, investigating and verifying my insurance benefits, coordinating the dispensing and delivery of medication, and conducting the additional services described above and to run the Program, including internal business purposes.

## In addition, by signing on page 2, I understand and agree that:

- I may refuse to sign the form on page 2. This authorization is voluntary, but if I refuse to sign this form, I know that this means that I may no longer be eligible to receive assistance from the Program. I understand that my doctor(s), pharmacy and other healthcare providers, and my health plan or insurers may not condition the provision of my treatment, or coverage of my benefits, on my signing this authorization.
- Health Information released under this authorization may no longer be protected by state and federal law, including the Health Insurance Portability and Accountability Act (HIPAA).
- The information provided in this application may be subject to random audits and verification, and that during such audits and verification processes, I may be asked for additional supporting documentation and will comply with such requests.
- I may withdraw my authorization at any time by mailing a written withdrawal to JJPAF at PO Box 0367, Chesterfield, MO 63006, however, such withdrawal will not have an impact on any actions that have already been taken in reliance on this authorization.
- This authorization will last until I am no longer participating in the Program or sooner as limited by applicable state law.
- I have a right to receive a copy of this authorization.

#### DO NOT SUBMIT THIS PAGE—IT IS FOR PATIENT AND HEALTHCARE PROFESSIONAL RECORDS ONLY

## **Patient Assistance Program Application**

Johnson Johnson PATIENT ASSISTANCE FOUNDATION, INC.

# HEALTHCARE PROFESSIONAL AUTHORIZATION: JJPAF POLICY AND TERMS & CONDITIONS AGREEMENT Please read, sign and date on page 3, HCP Section 3.

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) policy prohibits Healthcare Professionals (HCPs) from charging patients any fee for enrollment or other activities associated solely with the patient's participation in the Patient Assistance Program ("Program").

- JJPAF requests that HCPs not charge the patient for those professional services associated with this regimen not covered by the patient's health insurer.
- No claim may be made to any third-party payer (e.g., Medicaid, Medicare, private insurance, etc.) for payment for product provided under the Program.
- In accordance with the CMS Medicare Policy Manual, CMS will not reimburse you for any free product donated from JJPAF. In addition, in accordance with our eligibility criteria, Medicare Part B patients may receive free physician-administered product from JJPAF when such product is not covered by CMS. In such a case, and according to CMS policy, claims for administration services may not be reimbursed. You accept product from JJPAF with this understanding.
- The products(s) provided under the Program may not be sold or traded and may not be returned for credit.
- The JJPAF Program is limited to patients being treated on an outpatient basis.
- JJPAF and the vendors associated with administrating the Program (collectively, the "Program Administrators") reserve the right to request additional information if needed and to change or terminate the Program at any time, without notice.
- JJPAF and the Program Administrators reserve the right to refuse to distribute the medications under this program to any patient or facility at any time, without notice.

## Indicate your agreement to the terms of the JJPAF Program participation by signing on page 3. Your signature is intended to confirm to JJPAF:

- There is a valid medical need for this patient's prescription.
- I authorize JJPAF or its affiliated companies or subcontractors to forward the patient's prescription to a dispensing pharmacy on behalf of the patient.
- I authorize JJPAF to use my provider information, including National Provider ID # to determine a patient's eligibility in the Program.
- That to the best of your knowledge this patient does not have prescription drug insurance coverage for the product(s) listed above.
- For SIRTURO®\*, if the patient has been diagnosed with pulmonary multi-drug resistant tuberculosis (MDR-TB), appropriate notification has been made to the local (state) health department.
- For SPRAVATO®\*, the healthcare setting will be certified in the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) and the patient will be enrolled in the SPRAVATO® REMS. SPRAVATO® will not be dispensed directly to this patient for home use.
- You are not prohibited from participating in Federally funded healthcare programs nor are you on the List of Excluded Individuals/ Entities maintained by the HHS Office of Inspector General.
- That the medication(s) provided to you by the Program will not be provided or dispensed to any other person.
- I have a signed copy on file of my patient's current and completed patient authorization to share health information in accordance with HIPAA, or any other authorization or consent required by law, so that you may share patient health information with the Program, including the JJPAF Recipients.
- I understand that the information provided in this application may be subject to random audits and verification and that, during such audits and verification processes, I may be asked for additional supporting documentation and will comply with such requests.